Immunoclin Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-04-11: Form 8-K; Period of report 2016-04-04; Description 1.02 Termination of a Material Definitive Agreement; Details 1.02.
- 2016-04-04: Form 8-K; Period of report 2016-04-01; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
- 2016-03-11: Form 8-K; Period of report 2016-03-10; Description 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events; Details 5.03.
- 2014-08-01: Form 8-K; Period of report 2014-08-01; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-04-11 | 8-K | 2016-04-04 | 1.02 Termination of a Material Definitive Agreement | 1.02 On April 4, 2016, Immunoclin Corporation, a Nevada corporation, previously known as Pharma Investing News, Inc. (the “Company”), took the following actions: (i) the Company terminated the Management Agreement dated as of April 5, 2013 (the “MA”), by and between the Company and Castor Management Services, Inc. (“Castor”), pursuant to which agreement Castor was engaged to provide certain consulting services to the Company and (ii) the Company terminated, with respect to Castor, the Control Shareholder Agreement dated as of December 13, 2013 (the “CSA”), by and among Castor and other parties. | v436684_8k.htm |
| 2016-04-04 | 8-K | 2016-04-01 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On April 1, 2016, the Board of Directors of Immunoclin Corporation (the “Company”) dismissed Turner, Stone & Company (“Turner”) as the Company’s independent registered public accounting firm, not for cause or any disagreement, effectively immediately. | v436106_8k.htm |
| 2016-03-11 | 8-K | 2016-03-10 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 On March 10, 2016, the Board of Directors of Immunoclin Corporation, a Nevada corporation (the “Company”) amended Article I of the Company’s Bylaws, as currently in effect (the “Bylaws”), to reflect the address of the Company’s new executive offices. 8.01 Effective as of March 10, 2016, the Company has changed its corporate address to 1420 N Street, Suite 102, Washington, DC 20005, USA. | v433921_8k.htm |
| 2014-08-01 | 8-K | 2014-08-01 | 8.01 Other Events | 8.01 As of August 1, 2014, Immunoclin Corporation (the “Company”) will change its corporate headquarters to 1800 Wyoming Avenue, NW, 3rd Floor, Washington, DC 20009. | form8k.htm |
| 2014-07-08 | 8-K | 2014-07-02 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On July 2, 2014, Immunoclin Corporation (the “Company”) dismissed Sadler, Gibb & Associates, LLC (“Sadler Gibb”) as the Company’s principal accountant. | form8k.htm |
| 2014-03-04 | 8-K | 2014-01-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | form8k.htm |
| 2014-02-27 | 8-K/A | 2013-12-13 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 Entry into a Material Definitive Agreement. 2.01 Completion of Acquisition or Disposition of Assets. 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. | form8k.htm |
| 2014-02-06 | 8-K | 2014-01-29 | 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 8.01 Other Events | 3.02 On February 5, 2014, Immunoclin Corporation (the “Company”) issued 1,000,000 shares of Series A Preferred Stock to certain Shareholders of the Company. 3.03 On January 30, 2014, the Company filed a Certificate of Designation of Series A Preferred Stock (the "Certificate of Designation”) with the Nevada Secretary of State designating 1,000,000 of the Company's previously authorized preferred stock. 8.01 On January 29, 2014, the Company received approval from FINRA for its previously announced name change. | form8k.htm |
| 2013-12-20 | 8-K | 2013-11-08 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.01 Entry into a Material Definitive Agreement. 2.01 Completion of Acquisition or Disposition of Assets. 3.03 Material Modification to Rights of Security Holders. 5.01 Changes in Control of Registrant. 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 5.03 Change the Company’s name to ImmunoClin Corporation. | form8k.htm |
| 2013-05-01 | 8-K | 2013-04-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On April 25, 2013, the Company received a resignation notice from Robert Lawrence from all of his positions with the Company, including President, CEO, Principal Executive Officer, Treasurer, CFO, Principal Accounting Officer, Secretary, Treasurer and as Director. 8.01 Effective April 25, 2013, the Company has moved its executive offices to 9107 Wilshire Blvd., Suite 450, Beverly Hills, California 90210. | form8k.htm |
| 2012-10-16 | 8-K | 2012-09-17 | 8.01 Other Events | 8.01 On September 17, 2012, Carrillo Huettel, LLC, resigned as legal counsel to Pharma Investing News, Inc. (the “Company”). | f8k081512_8k.htm |